Next Article in Journal
Evaluation of the Antioxidant and Neuroprotectant Activities of New Asymmetrical 1,3-Diketones
Next Article in Special Issue
The Effect of Long-Term Administration of Fatty Acid Amide Hydrolase Inhibitor URB597 on Oxidative Metabolism in the Heart of Rats with Primary and Secondary Hypertension
Previous Article in Journal
Stereoselective and Simultaneous Analysis of Ginsenosides from Ginseng Berry Extract in Rat Plasma by UPLC-MS/MS: Application to a Pharmacokinetic Study of Ginseng Berry Extract
Previous Article in Special Issue
In Vitro Inhibitory Effects of Synthetic Cannabinoid EAM-2201 on Cytochrome P450 and UDP-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 23
Issue 8
10.3390/molecules23081836
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Cannabinoid CB2 Receptor Gene and Environmental Interaction in the Development of Psychiatric Disorders

by
Hiroki Ishiguro
1,*,
Yasue Horiuchi
2,
Koichi Tabata
1,
Qing-Rong Liu
3,
Tadao Arinami
4 and
Emmanuel S. Onaivi
5,*
1
Department of Neuropsychiatry and Clinical Ethics, Graduate School of Medical Science, University of Yamanashi, Chuo, Yamanashi 409-3898, Japan
2
Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Setagaya, Tokyo 156-8506, Japan
3
National Institute on Aging-IRP, NIH, Baltimore, MD 21224, USA
4
Department of Medical Genetics, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan
5
Department of Biology, William Paterson University, Wayne, NJ 07470, USA
*
Authors to whom correspondence should be addressed.
Molecules 2018, 23(8), 1836; https://doi.org/10.3390/molecules23081836
Submission received: 24 May 2018 / Revised: 18 July 2018 / Accepted: 20 July 2018 / Published: 24 July 2018
(This article belongs to the Special Issue Emerging Topics in (Endo)Cannabinoid Signalling)
Browse Figures
Versions Notes

Abstract

:
CB2 cannabinoid receptor (CB2R) gene is associated with depression. We investigated the gene-environment interaction between CB2R function and diverse stressors. First, anxiety-like behavior during chronic-mild-stress (CMS) was evaluated in C57BL/6JJmsSlc mice following treatment with CB2R agonist JWH015 or inverse-agonist AM630. Second, locomotor activity and anxiety-like behavior were measured following exposure to an immune poly I:C stressor. Gene expressions of HPA axis related molecules, Fkbp5, Nr3c1 and Crf and pro-inflammatory cytokine Il-1b, as well as Bdnf as a key neurotrophin that supports neuron health, function, and synaptic plasticity, were determined in hippocampus of Cnr2 knockout mice, as indicators of stressful environment. CMS-induced anxiety-like behavior was enhanced by AM630 and reduced by JWH015 and fluvoxamine. Poly I:C reduced locomotor activity and increased anxiety-like behavior, and these effects were pronounced in the heterozygote than in the wild type mice. Fkbp5 and Nr3c1 expression were lower in the Cnr2 heterozygotes than in the wild type mice with Poly I:C treatment. These findings indicate that interaction between CB2R gene and stressors increases the risk of depression-like behaviors that may be linked with neuro-immune crosstalk. Further studies in human subjects are necessary to determine the role of CB2R and environmental interaction in the development of depression.

1. Introduction

While most studies focus on the CB1 receptor (CB1R), recognition of the importance of understanding the roles of the cannabinoid CB2 receptor (CB2R) in the central nervous system in neuropsychiatric disorders has been increasing [1]. Reduced function of the CB2R is associated with several psychiatric disorders including schizophrenia, major depression, and substance abuse [2,3,4], but these genetic findings need to be validated by behavioral experiments with animal models of psychiatric disorders. The polymorphisms in the CB2R gene (CNR2) are frequent, and are commonly observed in human population [2] associated with psychiatric disorders [5]. In addition, our studies on the association of human CNR2 gene polymorphisms suggested that these polymorphisms are a common factor in some psychiatric disorders. We have previously demonstrated that Cnr2 gene expression was downregulated in the brains of the mice subjected to chronic-mild-stress (CMS) and also in mice that developed alcohol preference [3].
The endocannabinoid system appears to contribute to stress response, including activation of the hypothalamic-pituitary-adrenal (HPA) axis and increases in anxiety-related behavior during stress [6]. As stress responses involves the HPA axis and affect the onset and maintenance of stress-related disorders including depression [7], genes that play a role in the HPA-axis regulation may likely contribute to stress-related disorders. Within the canonical HPA axis, we examined the FKBP5, CRF and NR3C1 in this study. FKBP5, a co-chaperone of hsp90, is responsible for regulation of GR sensitivity to cortisol [8,9]. FKBP5 has been reported to be one of the biomarkers for stress-response and for effects of antidepressant action in patients with depression [8,10,11,12]. The NR3C1, encoding GR, is known as a major component of HPA axis against stress, and have been reported to be one of stress biomarkers with responses to psychosocial stress following the Trier Social Stress Test (TSST) [13]. The polymorphisms, methylation and expression of the NR3C1 gene have been indicated to be associated with depression and especially related to stress [14,15,16,17,18,19]. The CRF gene, that codes corticotropin-releasing factor, contributes to stress-related depressiveness [20]. We hypothesized that if the endocannabinoid system is involved in HPA axis, then the expression of Fkbp5, Crf and Nr3c1 genes may be associated with changes in CB2R function in mice. Neuro-immune crosstalk mediated by stressors is an important target of study in psychiatric disorders. Previous studies have indicated changes in expression of cytokines in psychiatric disorders [21,22,23,24,25,26,27,28,29]. Differences in proinflammatory cytokines produced by monocytes between patients with major depressive disorder and healthy controls [30]. Exposure to chronic restraint stress exacerbated allodynia and depressive-like behavior along with increase in Interleukin 1β (IL-1β) gene expression [31]. GR antagonist reduced depression-like behaviors induced by Il-1b administration in rodent model [32]. Brain-derived neurotrophic factor (BDNF) gene expression in blood was found to be negatively associated with depression score (HAMD) [33], and Bdnf/trkB signaling was reduced in the hippocampus of genetic model of vulnerability to stress-induced depression [34]. We therefore examined Il1b and Bdnf gene expressions that have been implicated as biomarkers for depression.
The endocannabinoid system is associated with stress-induced psychiatric disorders. Chronic-mild-stress (CMS) has been developed on the basis of stress-diathesis hypothesis of depression [35]. The viral mimic polyinosinic-polycytidilic acid, Poly I:C is a synthetic double-stranded RNA which activates the Toll-like receptor 3 (TLR3) pathway, and which is used in animal model of depression [36]. Therefore, the effects of CMS and Poly I:C treatments were analyzed in this study to simulate stressors such as emotional and immune stressors.
The aim of this study was to determine the role of CB2Rs and environmental factors on behavioral characteristics of mouse models of depression using two stressors, and to evaluate neuro-inflammatory and HPA axis biomarkers in the stress models. This study is a first report of our research focusing on the gene-environment interaction between CB2R and stressors in the mature mouse.

2. Results

All statistical results for both behavioral and gene expression analysis are shown in Table 1.

2.1. Behavioral Analysis

We examined whether two important components of depressive behavior, anxiety and hypoactivity using the stressed animals. In the Zero maze test, there were no differences in the percent time spent in open section between the wild type and the heterozygote Cnr2 KO mice where all the mice were naïve (Table 1).
As stress model, CMS enhanced anxiety-like behavior of the JJmsSlc mice in Zero maze compared with that of the CMS-naïve mice. CMS differentially altered the anxiety-like behavior of mice treated with saline, CB2R agonist, inverse agonist and fluvoxamine (Figure 1 and Table 1). After CMS, AM630 treatment significantly augmented the anxiety-like behavior compared with the saline treated mice. In contrast, JWH015 reduced the anxiety-like behavior induced by CMS, which was similar to the effect of antidepressant fluvoxamine (Figure 1 and Table 1).
Treatment with Poly I:C reduced the percent time spent in the open section of the Zero maze, indicating an anxiety-like behavior that was enhanced in the heterozygote Cnr2 knockout mice than in the wild type mice (Figure 2 and Table 1).
Similar anxiety-like behavior were obtained with the number of rotation of the pulley in the test box, with the pulley placed half-sunk into water (Figure 3 and Table 1). It is also important to evaluate a possibility that stressed mice show hypolocomotion. In the locomotor activity test there was no significant difference but there was a tendency for the heterozygote Cnr2 KO mice to reduce their locomotor activities in their home cages compared to the wild type mice during 72 h after the Poly I:C injection (Figure 4 and Table 1). Poly I:C, that is known known to induce immune stress, reduced the locomotor activity of mice and provoked anxiety-like behavior, which was apparent in the Cnr2 heterozygotes than in the wild type mice. This provides additional evidence that components of the endocannabinoid system, including Cb2r are implicated in regulating the stress response and involved in neuro-immune signaling underlying depression

2.2. Gene Expression

It has not been clearly understood, neuro-immune and HPA axis function seemed to work in vulnerability to psychiatric disorders, and either in development or in result of the disorders. Thus some molecules had been indicated as biomarker for stress and/or depression. Our study could support the biomarker related to HPA axis. CMS reduced the Fkbp5 gene expression significantly in the hippocampus of C57B/JJmsSlc mice (Figure 5 and Table 1).
Poly I:C treatment significantly reduced the expression of Fkbp5 in the Cnr2 heterozygote KO mice than in the wild type controls, while the saline treatment had no effect in the expression of Fkbp5 in mice (Figure 6 and Table 1).
There was a significant reduction in the expression of Nr3c1 gene in the heterozygotes than in the wild type mice after Poly I:C treatment, and no differences was found in the expression of Nr3c1 in the saline-treated mice between the genotypes. (Figure 7 and Table 1).
However, there were no difference in the expression of Crf gene in the hippocampus between the genotype of the mice and between saline and Poly I:C treatments. Regard of neuro-inflammation signaling, although the expression of interleukin Il1b gene seemed to be more in the heterozygotes than in the wild type mice with Poly I:C treatment, Tukey test did not show any difference between each group. (Figure 8 and Table 1). The stressors used in this study reduced Fkbp5 and Nr3c1 gene expressions in hippocampus associated with emotionality and reward pathways and reveals a role for CB2Rs in the mouse models of depression.

3. Discussion

There is increasing evidence that cannabinoid CB2 receptors (CB2Rs) are involved in brain function and in neuropsychiatric disorders. The present study indicates that genetically induced low function of the CB2Rs increases susceptibility to depression when combined with emotional (CMS) and immune (poly I:C) stressors. This is consistent with our previous reports that low CB2R function induces depression-like symptoms in the mouse model and alcohol addiction in human population [3]. FKBP5/Fkbp5 is one of the biomarkers for posttraumatic stress disorder (PTSD): The FKBP5 gene expression was reported to be low but elevated during cognitive behavioral therapy (CBT) in PTSD patients [37,38]. Consistent with the PTSD study, the results from our experiments using a mouse model demonstrated a reduction of the Fkbp5 gene expression after CMS. However, another study reported that CMS increased Fkbp5 protein expression, which was not observed in rats with adrenalectomy [39]. The reason for the difference is not clear, but may be due to species’ difference, and difference in measurements or CMS procedures utilized. It this study, reduced Fkbp5 gene expression in hippocampus is indicated to be a biomarker for the developed anxiety-like behavior developed by CMS (C vs. SS in Figure 1 and Figure 5). Reduced Fkbp5 and Nr3c1 gene expressions in the brain of the Cnr2 heterozygote knockout mice in comparison to wild type mice indicated the developed anxiety-like behavior by Poly I:C stress shown in rotated pulley test (Figure 3, Figure 6 and Figure 7), which are also useful as biomarkers, although the anxiety behavior shown in Zero maze test seemed not to be very distinct parallel to the alteration of Fkbp5 expression in mice brain (Figure 2, Figure 6 and Figure 7).
There is also growing interest in role of neuro-immune crosstalk and signaling in the development of psychiatric disorders [40]. CB2Rs are linked to the immune system function in the periphery and CNS, and are involved in neural progenitor proliferation in the hippocampus [41,42]. In this study, Poly I:C, known to produce immune stress, decreased the locomotor activity of mice and increased their anxiety-like behavior, which was apparent in the Cnr2 heterozygotes than in the wild type mice. This provides additional evidence for the involvement of endocannabinoid system in neuro-immune reaction of the central nervous system underlying depression.
The current study examined environmental risk factors in the mature brain in the mouse as model of depression. However human patients may show vulnerability to certain types of stressors in developing psychiatric conditions like depression and schizophrenia that may be age dependent. For example, maternal immune activation (MIA) and adolescent cannabinoid exposure (ACE) have both been identified as major environmental risk factors for schizophrenia [43]. Cannabis use in adolescents was reported to be one of the risk factors for schizophrenia [44] and recent work with animal models demonstrated that adolescence would be a vulnerable period for developing schizophrenia [45]. Although influence of MIA on schizophrenia development was not clear in the general population, more studies of the interaction of MIA and the endocannabinoid system are needed. This is because neonatal rats experiencing maternal deprivation showed anomalous behaviors in adulthood which are also observed in schizophrenic patients [46]. Furthermore, similar mechanisms could occur in development of stress-related disorders, including depression, anxiety disorders and alcoholism [47,48], which could be observed also in “depressive-like” animal model [49]. Animal studies indicated that early maternal deprivation is associated with increase in the number of degenerating hippocampal neurons and astrocytes and increased corticosterone and implicating the endocannabinoid system as 2-AG levels increased in the hippocampus [50,51]. Long-term changes in monoamines and Bdnf, as well as in HPA-axis function, were induced by early maternal deprivation [52,53]. Further studies are needed for age-dependent distress on development of stress-related disorders including depression.
In the present study, Poly I:C treatment differentially altered the expression of Fkbp5 and Nr3c1 in brains of mice stressed with Poly I:C either between genotypes of mice or in contrast to saline treatment. The alteration of IL-1β level, as well as that of BDNF [33,54], has been observed in major depressive patients, according to systematic Review and Meta-Analysis [28]. In the present study, Poly I:C treatment differentially altered the expression of interleukin Il1b gene in the striatum between the Cnr2 heterozygotes and the wild type mice. It remains unclear whether the specific cytokine affects the neural system to develop depression uniquely. Each stressor affects different cytokines, which causes different neuro-immune reaction induced endophenotypes that lead to different psychiatric disturbances. Further studies on the roles of cytokines in brain pathology are now focused on revealing the risks of combining specific stressors and vulnerable ages in the development of depression, schizophrenia, and other psychiatric diseases. Transcriptome analysis of cytokine expression in animals as well as in human patients is also necessary to understand the specific roles of CB2Rs and interaction with HPA axis and neuro-immune signaling in psychiatric disorders.
The present study has two limitations; first, it was performed in animal models for depression and needs to be tested in human subjects. Second, we examined whether adult brain stressors would lead to the development of psychiatric symptoms. While acute stressors may cause depression in human adults, future studies of possible interactions between hypomorphic CB2R function and the impact of stressors are required to characterize the developmental roles of the CB2Rs in psychiatric disorders.

4. Materials and Methods

The experimental design and the tested animals in this study were summarized in Table 2. All study participants provided informed consent, and the study design was approved by the Research Ethics Committee of Faculty of Medicine, University of Yamanashi and the Research Ethics Committee of University of Tsukuba, Japan.

4.1. Subjects

Mice were housed under 12 h light/12 h dark cycle and with food and water ad libitum. Two strains of mice were used in this study. The first group, Cnr2 knockout mice were provided by Prof. Buckley [55] and the heterozygous mating pairs were obtained from the same litter and were bred by heterozygote-heterozygote breeding strategies so that the average genetic backgrounds of the knockout mice were identical to produce the cohorts used in this study. In order to represent human subjects with genetically low CB2 receptor function, we did not use homozygote Cnr2 knockout mice. The second group, C57BL/6JJmsSLC mice (Japan SLC, Inc., Shizuoka, Japan) were treated with CB2R ligands and used for CMS test. Mice were group housed. The study was approved by the Institutional Animal Care and Use Committee at University of Yamanashi and at University of Tsukuba.

4.2. Behavioral Analysis

Behavioral changes were analyzed following the application of two stressors to determine the functional relationship of the stressors with CB2Rs. The application of CMS and immune stressor using Poly I:C to the animals were analyzed for possible roles in anxiety-like and depression-like behaviors. All behavioral tests were performed during light phase.

4.3. Anxiety-Like Behavioral Test

The CMS treatment was implemented as follows: mice were housed separately from other mice in home cages with either no-food, no-water, tilted and no-bedding tips, wet bedding, or strobe-light with heat, which were applied twice daily for 2 weeks. C57BL/6JJmsSlc male mice (age, 8–10 weeks: weight, 20–25 g: n = 8–11 for each group) (Japan SLC, Inc.) were divided into five groups. Group one (n = 9) was a control without CMS treatment. Groups two through five were given CMS, with each group (n = 8–11) concurrently injected intraperitoneally with either saline, CB2 inverse agonist AM630 (3 mg/kg), CB2 agonist JWH015 (20 mg/kg), or fluvoxamine (30 mg/kg). Their trend of anxiety was measured by elevated Zero maze (San Diego Instruments Inc., San Diego, CA, USA), in order to evaluate a simple influence from chronic mild stress without additional stresses, such as forced swimming, we chose Zero maze for suitable experiment in this study [56]. Briefly, each mouse is free to walk for 5 min on circular elevated passage that is divided into 4 equal portions. Two opposite sections have walls on both sides (enclosed) while the other two opposite sections have no walls (open). The time spent in enclosed section was measured and regarded as anxiety-like behavior. Next, the effect of immune stressor with poly I:C was analyzed. Cnr2 knockout and naive male mice (age, 8–10 weeks: weight, 20–25 g: n = 19–49 for each group) were pre-administered intraperitoneally (ip) with Poly I:C (6 mg/kg) were used for anxiety-like behavioral test in the elevated Zero maze and in a new model to access anxiety-like behavior. Briefly, this new anxiety test was performed in the test box where a pulley was placed half-sunk into water, because commonly used forced-swim test itself has given additional inconsiderable stress onto the test mice [56]. When each mouse to be tested was put beside the pulley, we counted how many times he rotated the pulley in order to try to get out of the water during five minutes test period. The test was initiated 30 s after the mice were placed in the water.

4.4. Locomotor Activity Test

Cnr2 heterozygote knockout male mice (age, 8–10 weeks: weight, 20–25 g: 5 Poly I:C treated and 9 saline treated wild type mice, and 15 Poly I:C treated and 10 saline treated heterozygote mice) administered intraperitoneally with Poly I:C (6 mg/kg) were monitored individually for locomotor activity in the home cages. Locomotor activity was measured by an activity monitoring system (ACTIMO-100; Shinfactory, Fukuoka, Japan) using ACTIMO-DATA software [57] Data were collected every 30 min for 72 h.

4.5. Gene Expression Analysis

Fkbp5 gene expression, as biomarker of depression and stress-related disorders (Figure 5), was analyzed in the hippocampus from the mice subjected to CMS and immunologically stressed (Poly I:C). To confirm the role of CB2R in HPA axis, nuclear receptor subfamily 3 group C member 1 (Nr3c1) and corticotropin releasing hormone (Crf) gene expressions were analyzed in immunologically stressed (Poly I:C) mice. Interleukin(Il) 1β and Bdnf gene expressions were analyzed for stress induced neuro-immune reaction in the mice. Total RNA was extracted from the brain tissue with RNeasy Mini Kit (QIAGEN, Hombrechtikon, Switzerland). cDNA was synthesized with Revertra Ace (Toyobo, Tokyo, Japan) and oligo dT primer from RNA. Expression of target genes was analyzed with an ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA) with the TaqMan gene expression assays for Fkbp5 (Mm00487406_m1), Nr3c1 (Mm00433832_m1), Crf (Mm001293920_m1) and Il1b (Mm00434228_m1). Rodent GAPDH Control Reagents (#4308313, Applied Biosystems) was used to normalize the target gene expression. TaqMan assay was performed in 10 μL reaction volumes. Measurement of threshold cycle (Ct) was the average of four replicates.

4.6. Statistics

Percent time-spent in Zero maze, and rotation number in another anxiety test were analyzed by two-way ANOVA, followed by post-hoc analysis for comparison of the locomotion at each time-period using the Tukey’s test. Locomotor activity was compared between groups of mice with different treatments by two-way ANOVA. The difference of expression level of Fkbp5 gene in JJmsSlc mice with between naïve and CMS was analyzed by one-way ANOVA. The difference of expression level of Fkbp5 gene in JJmsSlc mice with between naïve and CMS was analyzed by one-way ANOVA. The difference of expression level of each other gene between knockout mice genotypes in either treatment was analyzed by two-way ANOVA, followed by post-hoc analysis using the Tukey’s test. ANOVA and Tukey’s tests were carried out by using JMP software version 13 (SAS Institute, Japan).

5. Conclusions

In conclusion, reduced CB2R function in the endocannabinoid system plays a role in the occurrence of anxiety-like and depression-like related behaviors, during exposure to environmental stressors. This study provides evidence that cannabinoid CB2 receptors could be a potential target, and CB2R agonists may be therapeutic ligands for psychiatric disorders like depression.

Author Contributions

H.I., T.A. and E.S.O. designed the study and obtained grants to fund it. H.I., Y.H. and K.T. performed the experiments and statistical analysis. H.I. wrote the manuscript, and Q.-R.L. reviewed and E.S.O. revised the manuscript and contributed on the interpretation of findings.

Funding

H.I. was supported by Public Interest Trust Research Aid Fund for Stress-Related Disease (with Commemoration of Imai Kimi), KAKENHI (18023009, 20023006, and 20390098). Y.H. is supported by Tokyo Metropolitan Institute of Medical Science. E.S.O. is supported by William Paterson University and the Dean’s student workers program, and was also supported by NIH grant DA032890.

Acknowledgments

The Cnr2 knockout mice were donated by Nancy Buckley, California State Polytechnic University. This article has been edited by a language editing service at William Paterson University, USA.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Onaivi, E.S.; Ishiguro, H.; Gu, S.; Liu, Q.R. CNS effects of CB2 cannabinoid receptors: Beyond neuro-immuno-cannabinoid activity. J. Psychopharmacol. 2012, 26, 92–103. [Google Scholar] [CrossRef] [PubMed]
  2. Ishiguro, H.; Horiuchi, Y.; Ishikawa, M.; Koga, M.; Imai, K.; Suzuki, Y.; Morikawa, M.; Inada, T.; Watanabe, Y.; Takahashi, M.; et al. Brain cannabinoid CB2 receptor in schizophrenia. Biol. Psychiatry 2010, 67, 974–982. [Google Scholar] [CrossRef] [PubMed]
  3. Ishiguro, H.; Iwasaki, S.; Teasenfitz, L.; Higuchi, S.; Horiuchi, Y.; Saito, T.; Arinami, T.; Onaivi, E.S. Involvement of cannabinoid CB2 receptor in alcohol preference in mice and alcoholism in humans. Pharmacogenomics J. 2007, 7, 380–385. [Google Scholar] [CrossRef] [PubMed]
  4. Onaivi, E.S.; Ishiguro, H.; Gong, J.P.; Patel, S.; Meozzi, P.A.; Myers, L.; Perchuk, A.; Mora, Z.; Tagliaferro, P.A.; Gardner, E.; et al. Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann. N. Y. Acad. Sci. 2008, 1139, 434–449. [Google Scholar] [CrossRef] [PubMed]
  5. Ishiguro, H.; Onaivi, E.S. Beyond the Kraepelinian Dichotomy of Schizophrenia and Bipolar Disorder. J. Schizophr. Res. 2017, 4, 1032. [Google Scholar]
  6. Morena, M.; Patel, S.; Bains, J.S.; Hill, M.N. Neurobiological Interactions between Stress and the Endocannabinoid System. Neuropsychopharmacology 2016, 41, 80–102. [Google Scholar] [CrossRef] [PubMed]
  7. Gerritsen, L.; Milaneschi, Y.; Vinkers, C.H.; van Hemert, A.M.; van Velzen, L.; Schmaal, L.; Penninx, B.W. HPA Axis Genes, and Their Interaction with Childhood Maltreatment, are Related to Cortisol Levels and Stress-Related Phenotypes. Neuropsychopharmacology 2017, 42, 2446–2455. [Google Scholar] [CrossRef] [PubMed]
  8. Binder, E.B. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology 2009, 34 (Suppl. 1), S186–S195. [Google Scholar] [CrossRef] [PubMed]
  9. Denny, W.B.; Valentine, D.L.; Reynolds, P.D.; Smith, D.F.; Scammell, J.G. Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding. Endocrinology 2000, 141, 4107–4113. [Google Scholar] [CrossRef] [PubMed]
  10. Gassen, N.C.; Hartmann, J.; Schmidt, M.V.; Rein, T. FKBP5/FKBP51 enhances autophagy to synergize with antidepressant action. Autophagy 2015, 11, 578–580. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Fabbri, C.; Hosak, L.; Mossner, R.; Giegling, I.; Mandelli, L.; Bellivier, F.; Claes, S.; Collier, D.A.; Corrales, A.; Delisi, L.E.; et al. Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response. World J. Biol. Psychiatry 2016, 7, 1–24. [Google Scholar] [CrossRef] [PubMed]
  12. Young, D.A.; Inslicht, S.S.; Metzler, T.J.; Neylan, T.C.; Ross, J.A. The effects of early trauma and the FKBP5 gene on PTSD and the HPA axis in a clinical sample of Gulf War veterans. Psychiatry Res. 2018, 2018, 32068-1. [Google Scholar] [CrossRef] [PubMed]
  13. Kumsta, R.; Entringer, S.; Koper, J.W.; van Rossum, E.F.; Hellhammer, D.H.; Wust, S. Sex specific associations between common glucocorticoid receptor gene variants and hypothalamus-pituitary-adrenal axis responses to psychosocial stress. Biol. Psychiatry 2007, 62, 863–869. [Google Scholar] [CrossRef] [PubMed]
  14. Palma-Gudiel, H.; Cordova-Palomera, A.; Tornador, C.; Falcon, C.; Bargallo, N.; Deco, G.; Fananas, L. Increased methylation at an unexplored glucocorticoid responsive element within exon 1D of NR3C1 gene is related to anxious-depressive disorders and decreased hippocampal connectivity. Eur. Neuropsychopharmacol. 2018, 28, 579–588. [Google Scholar] [CrossRef] [PubMed]
  15. Kang, H.J.; Bae, K.Y.; Kim, S.W.; Shin, I.S.; Kim, H.R.; Shin, M.G.; Yoon, J.S.; Kim, J.M. Longitudinal associations between glucocorticoid receptor methylation and late-life depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2018, 84, 56–62. [Google Scholar] [CrossRef] [PubMed]
  16. Sarubin, N.; Hilbert, S.; Naumann, F.; Zill, P.; Wimmer, A.M.; Nothdurfter, C.; Rupprecht, R.; Baghai, T.C.; Buhner, M.; Schule, C. The sex-dependent role of the glucocorticoid receptor in depression: Variations in the NR3C1 gene are associated with major depressive disorder in women but not in men. Eur. Arch. Psychiatry Clin. Neurosci. 2017, 267, 123–133. [Google Scholar] [CrossRef] [PubMed]
  17. Park, S.; Hong, J.P.; Lee, J.K.; Park, Y.M.; Park, Y.; Jeon, J.; Ahn, M.H.; Yoon, S.C. Associations between the neuron-specific glucocorticoid receptor (NR3C1) Bcl-1 polymorphisms and suicide in cancer patients within the first year of diagnosis. Behav. Brain Funct. 2016, 12, 22. [Google Scholar] [CrossRef] [PubMed]
  18. Yin, H.; Galfalvy, H.; Pantazatos, S.P.; Huang, Y.Y.; Rosoklija, G.B.; Dwork, A.J.; Burke, A.; Arango, V.; Oquendo, M.A.; Mann, J.J. Glucocorticoid Receptor-Related Genes: Genotype and Brain Gene Expression Relationships to Suicide and Major Depressive Disorder. Depress. Anxiety 2016, 33, 531–540. [Google Scholar] [CrossRef] [PubMed]
  19. Schatzberg, A.F.; Keller, J.; Tennakoon, L.; Lembke, A.; Williams, G.; Kraemer, F.B.; Sarginson, J.E.; Lazzeroni, L.C.; Murphy, G.M. HPA axis genetic variation, cortisol and psychosis in major depression. Mol. Psychiatry 2014, 19, 220–227. [Google Scholar] [CrossRef] [PubMed]
  20. Chen, L.; Li, S.; Cai, J.; Wei, T.J.; Liu, L.Y.; Zhao, H.Y.; Liu, B.H.; Jing, H.B.; Jin, Z.R.; Liu, M.; et al. Activation of CRF/CRFR1 signaling in the basolateral nucleus of the amygdala contributes to chronic forced swim-induced depressive-like behaviors in rats. Behav. Brain Res. 2018, 338, 134–142. [Google Scholar] [CrossRef] [PubMed]
  21. Kageyama, Y.; Kasahara, T.; Kato, M.; Sakai, S.; Deguchi, Y.; Tani, M.; Kuroda, K.; Hattori, K.; Yoshida, S.; Goto, Y.; et al. The relationship between circulating mitochondrial DNA and inflammatory cytokines in patients with major depression. J. Affect. Disord. 2017, 0327, 30661–30664. [Google Scholar] [CrossRef] [PubMed]
  22. Misiak, B.; Stanczykiewicz, B.; Kotowicz, K.; Rybakowski, J.K.; Samochowiec, J.; Frydecka, D. Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: A systematic review. Schizophr. Res. 2017, 9964, 30202–30205. [Google Scholar] [CrossRef] [PubMed]
  23. Wu, J.Q.; Chen, D.C.; Tan, Y.L.; Tan, S.P.; Xiu, M.H.; Wang, Z.R.; Yang, F.D.; Soares, J.C.; Zhang, X.Y. Altered interleukin-18 levels are associated with cognitive impairment in chronic schizophrenia. J. Psychiatr. Res. 2016, 76, 9–15. [Google Scholar] [CrossRef] [PubMed]
  24. Al-Hakeim, H.K.; Al-Rammahi, D.A.; Al-Dujaili, A.H. IL-6, IL-18, sIL-2R, and TNFalpha proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation. J. Affect. Disord. 2015, 182, 106–114. [Google Scholar] [CrossRef] [PubMed]
  25. Shirts, B.H.; Wood, J.; Yolken, R.H.; Nimgaonkar, V.L. Comprehensive evaluation of positional candidates in the IL-18 pathway reveals suggestive associations with schizophrenia and herpes virus seropositivity. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147, 343–350. [Google Scholar] [CrossRef] [PubMed]
  26. Xiu, M.H.; Chen, D.C.; Wang, D.; Zhang, K.; Dong, A.; Tang, W.; Zhang, F.; Liu, L.J.; Liu, J.H.; Liu, H.B.; et al. Elevated interleukin-18 serum levels in chronic schizophrenia: Association with psychopathology. J. Psychiatr. Res. 2012, 46, 1093–1098. [Google Scholar] [CrossRef] [PubMed]
  27. Zhang, X.Y.; Tang, W.; Xiu, M.H.; Chen, D.C.; Yang, F.D.; Tan, Y.L.; Wang, Z.R.; Zhang, F.; Liu, J.; Liu, L.; et al. Interleukin 18 and cognitive impairment in first episode and drug naive schizophrenia versus healthy controls. Brain Behav. Immun. 2013, 32, 105–111. [Google Scholar] [CrossRef] [PubMed]
  28. Kohler, C.A.; Freitas, T.H.; Stubbs, B.; Maes, M.; Solmi, M.; Veronese, N.; de Andrade, N.Q.; Morris, G.; Fernandes, B.S.; Brunoni, A.R.; et al. Peripheral Alterations in Cytokine and Chemokine Levels after Antidepressant Drug Treatment for Major Depressive Disorder: Systematic Review and Meta-Analysis. Mol. Neurobiol. 2018, 55, 4195–4206. [Google Scholar] [CrossRef] [PubMed]
  29. Ellul, P.; Boyer, L.; Groc, L.; Leboyer, M.; Fond, G. Interleukin-1 beta-targeted treatment strategies in inflammatory depression: Toward personalized care. Acta Psychiatr. Scand. 2016, 134, 469–484. [Google Scholar] [CrossRef] [PubMed]
  30. Zhang, H.X.; Xu, Y.Q.; Li, Y.Y.; Lu, M.F.; Shi, S.X.; Ji, J.L.; Wang, L.W. Difference in proinflammatory cytokines produced by monocytes between patients with major depressive disorder and healthy controls. J. Affect. Disord. 2018, 234, 305–310. [Google Scholar] [CrossRef] [PubMed]
  31. Norman, G.J.; Karelina, K.; Zhang, N.; Walton, J.C.; Morris, J.S.; Devries, A.C. Stress and IL-1beta contribute to the development of depressive-like behavior following peripheral nerve injury. Mol. Psychiatry 2010, 15, 404–414. [Google Scholar] [CrossRef] [PubMed]
  32. Zhang, Y.P.; Wang, H.Y.; Zhang, C.; Liu, B.P.; Peng, Z.L.; Li, Y.Y.; Liu, F.M.; Song, C. Mifepristone attenuates depression-like changes induced by chronic central administration of interleukin-1beta in rats. Behav. Brain Res. 2018, 347, 436–445. [Google Scholar] [CrossRef] [PubMed]
  33. Yoshimura, R.; Kishi, T.; Atake, K.; Katsuki, A.; Iwata, N. Serum Brain-Derived Neurotrophic Factor, and Plasma Catecholamine Metabolites in People with Major Depression: Preliminary Cross-Sectional Study. Front. Psychiatry 2018, 9, 52. [Google Scholar] [CrossRef] [PubMed]
  34. Serra, M.P.; Poddighe, L.; Boi, M.; Sanna, F.; Piludu, M.A.; Corda, M.G.; Giorgi, O.; Quartu, M. Expression of BDNF and trkB in the hippocampus of a rat genetic model of vulnerability (Roman low-avoidance) and resistance (Roman high-avoidance) to stress-induced depression. Brain Behav. 2017, 7, e00861. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Zhu, S.; Shi, R.; Wang, J.; Wang, J.F.; Li, X.M. Unpredictable chronic mild stress not chronic restraint stress induces depressive behaviours in mice. Neuroreport 2014, 25, 1151–1155. [Google Scholar] [CrossRef] [PubMed]
  36. Reisinger, S.; Khan, D.; Kong, E.; Berger, A.; Pollak, A.; Pollak, D.D. The poly(I:C)-induced maternal immune activation model in preclinical neuropsychiatric drug discovery. Pharmacol. Ther. 2015, 149, 213–226. [Google Scholar] [CrossRef] [PubMed]
  37. Levy-Gigi, E.; Szabo, C.; Kelemen, O.; Keri, S. Association among clinical response, hippocampal volume, and FKBP5 gene expression in individuals with posttraumatic stress disorder receiving cognitive behavioral therapy. Biol. Psychiatry 2013, 74, 793–800. [Google Scholar] [CrossRef] [PubMed]
  38. Szabo, C.; Kelemen, O.; Keri, S. Changes in FKBP5 expression and memory functions during cognitive-behavioral therapy in posttraumatic stress disorder: A preliminary study. Neurosci. Lett. 2014, 569, 116–120. [Google Scholar] [CrossRef] [PubMed]
  39. Chen, J.; Wang, Z.Z.; Zuo, W.; Zhang, S.; Chu, S.F.; Chen, N.H. Effects of chronic mild stress on behavioral and neurobiological parameters—Role of glucocorticoid. Horm. Behav. 2016, 78, 150–159. [Google Scholar] [CrossRef] [PubMed]
  40. Meyer, U. Prenatal poly(i:C) exposure and other developmental immune activation models in rodent systems. Biol. Psychiatry 2014, 75, 307–315. [Google Scholar] [CrossRef] [PubMed]
  41. Cabral, G.A.; Griffin-Thomas, L. Emerging role of the cannabinoid receptor CB2 in immune regulation: Therapeutic prospects for neuroinflammation. Expert Rev. Mol. Med. 2009, 11, e3. [Google Scholar] [CrossRef] [PubMed]
  42. Palazuelos, J.; Aguado, T.; Egia, A.; Mechoulam, R.; Guzman, M.; Galve-Roperh, I. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J. 2006, 20, 2405–2407. [Google Scholar] [CrossRef] [PubMed]
  43. Hollins, S.L.; Zavitsanou, K.; Walker, F.R.; Cairns, M.J. Alteration of transcriptional networks in the entorhinal cortex after maternal immune activation and adolescent cannabinoid exposure. Brain Behav. Immun. 2016, 56, 187–196. [Google Scholar] [CrossRef] [PubMed]
  44. Chadwick, B.; Miller, M.L.; Hurd, Y.L. Cannabis Use during Adolescent Development: Susceptibility to Psychiatric Illness. Front. Psychiatry 2013, 4, 129. [Google Scholar] [CrossRef] [PubMed]
  45. Gomes, F.V.; Rincon-Cortes, M.; Grace, A.A. Adolescence as a period of vulnerability and intervention in schizophrenia: Insights from the MAM model. Neurosci. Biobehav. Rev. 2016, 70, 260–270. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Ratajczak, P.; Wozniak, A.; Nowakowska, E. Animal models of schizophrenia: Developmental preparation in rats. Acta Neurobiol. Exp. 2013, 73, 472–484. [Google Scholar]
  47. Bailey, K.A.; Baker, A.L.; McElduff, P.; Kavanagh, D.J. The Influence of Parental Emotional Neglect on Assault Victims Seeking Treatment for Depressed Mood and Alcohol Misuse: A Pilot Study. J. Clin. Med. 2016, 5, 88. [Google Scholar] [CrossRef] [PubMed]
  48. Wang, Q.; Dong, X.; Wang, Y.; Liu, M.; Sun, A.; Li, N.; Lin, Y.; Geng, Z.; Jin, Y.; Li, X. Adolescent escitalopram prevents the effects of maternal separation on depression- and anxiety-like behaviours and regulates the levels of inflammatory cytokines in adult male mice. Int. J. Dev. Neurosci. 2017, 62, 37–45. [Google Scholar] [CrossRef] [PubMed]
  49. Malkesman, O.; Lavi-Avnon, Y.; Maayan, R.; Weizman, A. A cross-fostering study in a genetic animal model of depression: Maternal behavior and depression-like symptoms. Pharmacol. Biochem. Behav. 2008, 91, 1–8. [Google Scholar] [CrossRef] [PubMed]
  50. Llorente, R.; Llorente-Berzal, A.; Petrosino, S.; Marco, E.M.; Guaza, C.; Prada, C.; Lopez-Gallardo, M.; Di Marzo, V.; Viveros, M.P. Gender-dependent cellular and biochemical effects of maternal deprivation on the hippocampus of neonatal rats: A possible role for the endocannabinoid system. Dev. Neurobiol. 2008, 68, 1334–1347. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  51. Lopez-Gallardo, M.; Llorente, R.; Llorente-Berzal, A.; Marco, E.M.; Prada, C.; Di Marzo, V.; Viveros, M.P. Neuronal and glial alterations in the cerebellar cortex of maternally deprived rats: Gender differences and modulatory effects of two inhibitors of endocannabinoid inactivation. Dev. Neurobiol. 2008, 68, 1429–1440. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Recamier-Carballo, S.; Estrada-Camarena, E.; Lopez-Rubalcava, C. Maternal separation induces long-term effects on monoamines and brain-derived neurotrophic factor levels on the frontal cortex, amygdala, and hippocampus: Differential effects after a stress challenge. Behav. Pharmacol. 2017, 28, 545–557. [Google Scholar] [CrossRef] [PubMed]
  53. Van Bodegom, M.; Homberg, J.R.; Henckens, M. Modulation of the Hypothalamic-Pituitary-Adrenal Axis by Early Life Stress Exposure. Front. Cell. Neurosci. 2017, 11, 87. [Google Scholar] [CrossRef] [PubMed]
  54. Page, G.G.; Corwin, E.J.; Dorsey, S.G.; Redeker, N.S.; McCloskey, D.J.; Austin, J.K.; Guthrie, B.J.; Moore, S.M.; Barton, D.; Kim, M.T.; et al. Biomarkers as Common Data Elements for Symptom and Self-Management Science. J. Nurs. Scholarsh. 2018, 50, 276–286. [Google Scholar] [CrossRef] [PubMed]
  55. Buckley, N.E. The peripheral cannabinoid receptor knockout mice: An update. Br. J. Pharmacol. 2008, 153, 309–318. [Google Scholar] [CrossRef] [PubMed]
  56. Commons, K.G.; Cholanians, A.B.; Babb, J.A.; Ehlinger, D.G. The Rodent Forced Swim Test Measures Stress-Coping Strategy, Not Depression-like Behavior. ACS Chem. Neurosci. 2017, 8, 955–960. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Maejima, Y.; Rita, R.S.; Santoso, P.; Aoyama, M.; Hiraoka, Y.; Nishimori, K.; Gantulga, D.; Shimomura, K.; Yada, T. Nasal oxytocin administration reduces food intake without affecting locomotor activity and glycemia with c-Fos induction in limited brain areas. Neuroendocrinology 2015, 101, 35–44. [Google Scholar] [CrossRef] [PubMed]
Sample Availability: Samples of the compounds are available from the authors.
Molecules 23 01836 g001 550
Figure 1. Cannabinoid CB2R ligands regulate CMS-induced anxiety-like behavior. The vertical axis shows %time spent in open section in Zero maze. Naïve is non-stressed control, and others are CMS treated mice. White bar is %time of the Naïve (non-stressed) mice, black bar is %time of the stressed with saline treatment mice (SS), red bar are %time of the stressed with AM630 treatment mice (AS), blue bar is %time of the stressed with JWH015 treatment mice (JS), and green line bar is %time of the stressed with fluvoxamine treatment mice (FS). Number of subjects for each group is indicated in parenthesis. Significant difference between the groups: * p = 0.015, ** p = 0.0016, *** p < 1 × 10−3.
Figure 1. Cannabinoid CB2R ligands regulate CMS-induced anxiety-like behavior. The vertical axis shows %time spent in open section in Zero maze. Naïve is non-stressed control, and others are CMS treated mice. White bar is %time of the Naïve (non-stressed) mice, black bar is %time of the stressed with saline treatment mice (SS), red bar are %time of the stressed with AM630 treatment mice (AS), blue bar is %time of the stressed with JWH015 treatment mice (JS), and green line bar is %time of the stressed with fluvoxamine treatment mice (FS). Number of subjects for each group is indicated in parenthesis. Significant difference between the groups: * p = 0.015, ** p = 0.0016, *** p < 1 × 10−3.
Molecules 23 01836 g001
Molecules 23 01836 g002 550
Figure 2. Anxiety-like behavior following immune stress induced by Poly I:C injection in Zero maze test. The vertical axis shows %time spent in the open section of the Zero maze. Light gray bar is %time of the wild type saline treated mice, white bar is %time of the heterozygote saline treated mice, black bar is %time of the wild type Poly I:C treated mice, and dark gray bar is %time of the heterozygotes Poly I:C treated mice. The higher %time spent in the open section indicates reduced anxiety-like behavior of the mice. * Significant difference was found between treatments in heterozygote knockout mice as shown (p = 0.003), while no difference was found in wild type mice.
Figure 2. Anxiety-like behavior following immune stress induced by Poly I:C injection in Zero maze test. The vertical axis shows %time spent in the open section of the Zero maze. Light gray bar is %time of the wild type saline treated mice, white bar is %time of the heterozygote saline treated mice, black bar is %time of the wild type Poly I:C treated mice, and dark gray bar is %time of the heterozygotes Poly I:C treated mice. The higher %time spent in the open section indicates reduced anxiety-like behavior of the mice. * Significant difference was found between treatments in heterozygote knockout mice as shown (p = 0.003), while no difference was found in wild type mice.
Molecules 23 01836 g002
Molecules 23 01836 g003 550
Figure 3. Anxiety-like behavior of mice in the rotated pulley model induced by Poly I:C injection. Mice that display anxiety-like behavior rotated the pulley faster in order to crawl up from water. The vertical axis shows number of pulley rotation. Light gray bar indicates the wild type saline treated mice, white bar represents the heterozygote saline treated mice, black bar represents the wild type Poly I:C treated mice, and dark gray bar represents the heterozygote Poly I:C treated mice. Number of subjects for each group is shown in parenthesis. There was * Significant difference between the genotypes when the mice were treated with Poly I:C (p = 0.03).
Figure 3. Anxiety-like behavior of mice in the rotated pulley model induced by Poly I:C injection. Mice that display anxiety-like behavior rotated the pulley faster in order to crawl up from water. The vertical axis shows number of pulley rotation. Light gray bar indicates the wild type saline treated mice, white bar represents the heterozygote saline treated mice, black bar represents the wild type Poly I:C treated mice, and dark gray bar represents the heterozygote Poly I:C treated mice. Number of subjects for each group is shown in parenthesis. There was * Significant difference between the genotypes when the mice were treated with Poly I:C (p = 0.03).
Molecules 23 01836 g003
Molecules 23 01836 g004 550
Figure 4. Locomotor activity of the Cnr2 heterozygote KO mice three days after Poly I:C injection. Locomotor activity of each mouse every 30 min for 72 h is plotted as a dot for the wild type and the heterozygote Cnr2 KO mice. The light gray fields shows the locomotor activity of saline treated mice, while dark gray field show that of Poly I:C treated mice. ANOVA analysis showed significant difference (p < 0.0001), especially for the effect of Poly I:C treatment (p < 0.0001), but not for the genotypes (p = 0.35) or the combination of Poly I:C treatment and genotypes (p = 0.17). However, post-hoc analysis showed a small but insignificant difference in locomotor activity between the genotypes when the mice were injected with Poly I:C (p (single sided) = 0.06).
Figure 4. Locomotor activity of the Cnr2 heterozygote KO mice three days after Poly I:C injection. Locomotor activity of each mouse every 30 min for 72 h is plotted as a dot for the wild type and the heterozygote Cnr2 KO mice. The light gray fields shows the locomotor activity of saline treated mice, while dark gray field show that of Poly I:C treated mice. ANOVA analysis showed significant difference (p < 0.0001), especially for the effect of Poly I:C treatment (p < 0.0001), but not for the genotypes (p = 0.35) or the combination of Poly I:C treatment and genotypes (p = 0.17). However, post-hoc analysis showed a small but insignificant difference in locomotor activity between the genotypes when the mice were injected with Poly I:C (p (single sided) = 0.06).
Molecules 23 01836 g004
Molecules 23 01836 g005 550
Figure 5. Fkbp5 gene expression in the hippocampus of the C57B/6JJmsSlc mice is altered by CMS. The vertical axis shows the relative Fkbp5 expression level in the hippocampus of CMS treated C57BL/6JJmsSlc mice in comparison to that of naïve mice. Black bar indicates the relative Fkbp5 expression of the stressed mice in comparison to that of naïve (non-stressed) mice indicated in white bar. Number of subjects for each group is shown in parenthesis. There was * Significant reduction of the expression of Fkbp5 in the hippocampus in mice with CMS (p = 0.013).
Figure 5. Fkbp5 gene expression in the hippocampus of the C57B/6JJmsSlc mice is altered by CMS. The vertical axis shows the relative Fkbp5 expression level in the hippocampus of CMS treated C57BL/6JJmsSlc mice in comparison to that of naïve mice. Black bar indicates the relative Fkbp5 expression of the stressed mice in comparison to that of naïve (non-stressed) mice indicated in white bar. Number of subjects for each group is shown in parenthesis. There was * Significant reduction of the expression of Fkbp5 in the hippocampus in mice with CMS (p = 0.013).
Molecules 23 01836 g005
Molecules 23 01836 g006 550
Figure 6. Analysis of the Fkbp5 gene expression in the hippocampus after Poly I:C treatment. The vertical axis shows the relative Fkbp5 expression level after Poly I:C or saline treatments for each genotype group (in comparison to saline treated wild type mice). Light gray bar indicates the wild type saline treated mice, white bar represents the heterozygote saline treated mice, black bar represents the wild type Poly I:C treated mice, and dark gray bar represents the heterozygote Poly I:C treated mice. Number of subjects in each group is shown in parenthesis. * Significant difference between the genotypes when the mice were treated with Poly I:C (p = 0.01).
Figure 6. Analysis of the Fkbp5 gene expression in the hippocampus after Poly I:C treatment. The vertical axis shows the relative Fkbp5 expression level after Poly I:C or saline treatments for each genotype group (in comparison to saline treated wild type mice). Light gray bar indicates the wild type saline treated mice, white bar represents the heterozygote saline treated mice, black bar represents the wild type Poly I:C treated mice, and dark gray bar represents the heterozygote Poly I:C treated mice. Number of subjects in each group is shown in parenthesis. * Significant difference between the genotypes when the mice were treated with Poly I:C (p = 0.01).
Molecules 23 01836 g006
Molecules 23 01836 g007 550
Figure 7. Analysis of the Nr3c1 gene expression in the hippocampus of Cnr2 KO mice treated with Poly I:C. The vertical axis shows the relative Nr3c1 expression level after Poly I:C treatment for each genotype group (in comparison to saline treated wild type mice). Light gray bar indicates the wild type saline treated mice, white bar represents the heterozygote saline treated mice, black bar represents the wild type Poly I:C treated mice, and dark gray bar represents the heterozygote Poly I:C treated mice. Number of subjects in each group is shown in parenthesis. * Significant difference between the genotypes when the mice were treated with Poly I:C (p = 0.007).
Figure 7. Analysis of the Nr3c1 gene expression in the hippocampus of Cnr2 KO mice treated with Poly I:C. The vertical axis shows the relative Nr3c1 expression level after Poly I:C treatment for each genotype group (in comparison to saline treated wild type mice). Light gray bar indicates the wild type saline treated mice, white bar represents the heterozygote saline treated mice, black bar represents the wild type Poly I:C treated mice, and dark gray bar represents the heterozygote Poly I:C treated mice. Number of subjects in each group is shown in parenthesis. * Significant difference between the genotypes when the mice were treated with Poly I:C (p = 0.007).
Molecules 23 01836 g007
Molecules 23 01836 g008 550
Figure 8. Analysis Il1b gene expressions in the hippocampus after poly I:C stress. The vertical axis shows the relative Il1b expression level after Poly I:C treatment for each genotype group (in comparison to saline treated wild type mice). Light gray bar indicates the wild type saline treated mice, white bar represents the heterozygote saline treated mice, black bar represents the wild type Poly I:C treated mice, and dark gray bar represents the heterozygote Poly I:C treated mice. The numbers of the subjects are shown in parenthesis. While two-way ANOVA indicated possible involvement of Il1b in genotype and Poly I:C treatment, post-hoc analysis with Tukey test did not show any significant differences between the groups.
Figure 8. Analysis Il1b gene expressions in the hippocampus after poly I:C stress. The vertical axis shows the relative Il1b expression level after Poly I:C treatment for each genotype group (in comparison to saline treated wild type mice). Light gray bar indicates the wild type saline treated mice, white bar represents the heterozygote saline treated mice, black bar represents the wild type Poly I:C treated mice, and dark gray bar represents the heterozygote Poly I:C treated mice. The numbers of the subjects are shown in parenthesis. While two-way ANOVA indicated possible involvement of Il1b in genotype and Poly I:C treatment, post-hoc analysis with Tukey test did not show any significant differences between the groups.
Molecules 23 01836 g008
Table
Table 1. Result of statistical analyses of the behavioral and gene expression data. The results of the statistical analysis for each experiment of the behavioral and gene expression data are shown. The numbers in parenthesis show the corresponding figures. The results by ANOVA are shown in general and in each effect. Post-hoc analysis with Tukey tests was performed where appropriate. Differences were considered significant at the a priori level of p < 0.05.
Table 1. Result of statistical analyses of the behavioral and gene expression data. The results of the statistical analysis for each experiment of the behavioral and gene expression data are shown. The numbers in parenthesis show the corresponding figures. The results by ANOVA are shown in general and in each effect. Post-hoc analysis with Tukey tests was performed where appropriate. Differences were considered significant at the a priori level of p < 0.05.
Behavioral Test Treatment/StrainStatics ANOVANoted by Post-Hoc Analysis
Behavior
Zero maze testSaline/Cnr2 ko mice (no Figure)F1,34 = 0.48, p = 0.49
Zero maze testPoly I:C/Cnr2 ko mice (Figure 1)F3,118 = 4.4, p = 0.0055Poly I:C vs. saline treated heterozygote mice; p = 0.0033
genotype F = 0.09, p = 0.76
treatment F = 7.7, p = 0.006
genotype × treatment F = 1.6, p = 0.20
pulley rotate testPoly I:C/Cnr2 ko mice (Figure 2)F3,110 = 4.8, p = 0.0034Poly I:C treated wildtype mice vs. heterozygote mice; p = 0.019
genotype F = 4.2, p = 0.04
treatment F = 8.2, p = 0.005
genotype × treatment F = 0.6, p = 0.42
Zero maze testCMS/C57B/JJmsSlc mice (Figure 3)F4, 46 = 19.0, p < 0.0001CMS treated vs. naïve mice; p = 0.0016
AM630 vs. Saline treated mice with CMS; p = 0.015
JWH015 vs. Saline treated mice with CMS; p < 1 × 10−3
Fluvoxamine vs. Saline treated mice with CMS; p < 1 × 10−3
JWH015 vs. Fluvoxamine treated mice with CMS; n.s.
Locomotion testPoly I:C/Cnr2 ko mice (Figure 4)t(1827) = 1.54, p (single sided) = 0.06
Gene expression
Fkbp5CMS/C57B/JJmsSlc mice (Figure 5)F1, 12 = 8.4, p = 0.0134
Fkbp5Poly I:C/Cnr2 ko mice (Figure 6)F3,58 = 4.6, p = 0.008Poly I:C treated wildtype mice vs. heterozygote mice; p = 0.048
genotype F = 2.6, p = 0.01Poly I:C treated vs. Saline treated wildtype mice; p = 0.025
treatment F = −1.9, p = 0.06Poly I:C treated wildtype mice vs. Saline treated heterozygote mice; p = 0.013
genotype × treatment F = −1.7, p = 0.08
Nr3c1Poly I:C/Cnr2 ko mice (Figure 7)F3,59 = 4.4, p = 0.008Poly I:C treated wildtype mice vs. heterozygote mice; p = 0.007
genotype F = 8.4, p = 0.005
treatment F = 0.83, p = 0.37
genotype x treatment F = 3.2, p = 0.078
Il1bPoly I:C/Cnr2 ko mice (Figure 8)F3,58 = 1.8, p = 0.17n.s. (Poly I:C treated wildtype mice vs. heterozygote mice; p = 0.14)
genotype F = 0.0004, p = 0.98
treatment F = 0.98, p = 0.33
genotype × treatment F = 4.05, p = 0.049
BdnfPoly I:C/Cnr2 ko mice (no figure)F3,59 = 0.15, p = 0.93n.s.
CrfPoly I:C/Cnr2 ko mice (no figure)F3,59 = 0.54, p = 0.66n.s.
genotype F = 0.49, p = 0.63
treatment F = 0.54, p = 0.59
genotype × treatment F = 0.97, p = 0.34
Table
Table 2. The experimental design and the tested animals. The stressors, chemicals administered to mice and behavioral tests used in the study are shown. The numbers in parenthesis in experimental treatment section show number of mice used.
Table 2. The experimental design and the tested animals. The stressors, chemicals administered to mice and behavioral tests used in the study are shown. The numbers in parenthesis in experimental treatment section show number of mice used.
StressorsExperimental TreatmentBehavioral TestsGene Expression Analysis
Physical/Emotional (Chronic mild stress)Control (10)
AM630 (9)
JWH015 (8)
Fluvoxamine (11)
Saline (10)		1. Zero mazeFkbp5
Control (7) vs. Saline (7)
ImmunePoly I:C (20)
Saline (19)		1. Locomotion in home cageFkbp5, Il1b, Nr3c1, Bdnf, Crf
Poly I:C (31) vs. Saline (29)
Poly I:C (70)
Saline (52)		2. Zero maze
Poly I:C (61)
Saline (53)		3. Pulley rotating test (originally developed test)

Share and Cite

MDPI and ACS Style

Ishiguro, H.; Horiuchi, Y.; Tabata, K.; Liu, Q.-R.; Arinami, T.; Onaivi, E.S. Cannabinoid CB2 Receptor Gene and Environmental Interaction in the Development of Psychiatric Disorders. Molecules 2018, 23, 1836. https://doi.org/10.3390/molecules23081836

AMA Style

Ishiguro H, Horiuchi Y, Tabata K, Liu Q-R, Arinami T, Onaivi ES. Cannabinoid CB2 Receptor Gene and Environmental Interaction in the Development of Psychiatric Disorders. Molecules. 2018; 23(8):1836. https://doi.org/10.3390/molecules23081836

Chicago/Turabian Style

Ishiguro, Hiroki, Yasue Horiuchi, Koichi Tabata, Qing-Rong Liu, Tadao Arinami, and Emmanuel S. Onaivi. 2018. "Cannabinoid CB2 Receptor Gene and Environmental Interaction in the Development of Psychiatric Disorders" Molecules 23, no. 8: 1836. https://doi.org/10.3390/molecules23081836

APA Style

Ishiguro, H., Horiuchi, Y., Tabata, K., Liu, Q.-R., Arinami, T., & Onaivi, E. S. (2018). Cannabinoid CB2 Receptor Gene and Environmental Interaction in the Development of Psychiatric Disorders. Molecules, 23(8), 1836. https://doi.org/10.3390/molecules23081836

Article Metrics

Back to TopTop